Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice!
You're amazed that stock is being sold bought and traded?
"Only resulted in 241K to the bank".... Only?? Compare that to few years back. This company is growing stronger and stronger as their business plan unfolds perfectly. The stock pps will catch up eventually IMO.
10Q out!!
http://ih.advfn.com/p.php?pid=nmona&article=66719017
Half a million in revenues for the quarter ending March 31st!!
Nice find!
50% increase is biohearts goal according to Mike Thomas. He stated this on yesterday's conference call.
I expect a PR summarizing the material IMO.
It was a great call. Those who fail to see what is happening with this company will be too late to the party.
Last half our to load up!! 1 hour left till we become aware of biohearts future revenue generating potentials!!
Let's go bioheart!!! Great news coming IMO!!
Ready for the fireworks
SUNRISE, FL / ACCESSWIRE / April 22, 2015 / Bioheart, Inc., a Florida Corporation (BHRT.OB) announces today that Kristin Comella's blog interview with Paul Knoepfler, the Knoepfler Lab Stem Cell Blog is available on line through the following link:
http://www.ipscell.com/2015/04/kristin-comella/
Kristin Comella is Bioheart's Chief Scientific Officer and a noted leader in the stem cell industry. Kristin's interview with Paul Knoepfler covers a review of Bioheart's clinical pipeline and patient and training business.
http://finance.yahoo.com/news/biohea...041900308.html
SUNRISE, FL / ACCESSWIRE / April 15, 2015 / Bioheart, Inc., a Florida Corporation (BHRT) announces today that it will hold a 1st Quarter Review Conference Call on Thursday, April 23rd, 2015 at 4:30 PM EDT. The call will highlight research and development, business and corporate accomplishments for the first quarter of 2015 and goals for the second quarter. Webinar and dial-in numbers for the conference call will be posted on Monday, April 20, 2015.
"We continue to advance on our plan and pathway to profitability," said Mike Tomas, President and Chief Executive Officer. "Each of our operating divisions: Bioheart, US Stem Cell Training, Vetbiologics and US Stem Cell Clinic have made strategic and tactical gains in the first quarter and we expect to build on our positive momentum as we continue through this year. We look forward to updating you on our accomplishments on April 23rd."
Awesome find Gs!!!
Definitely. 100% agree. This 10K coming up is going to be very telling in the type of exponential growth we can expect to see from here on. I expect a self sufficient BioHeart by Q4 or next year the latest. Phase 3 Trials should also commence this year based on what the company has shared with us shareholders. GLTA
Thanks GS
Yes it has and should close higher in anticipation for Thursday's conference call which should be a telling store of business expansion and increased revenues for Q1
Excellent news.
I like it a lot.
Nice solid close. Held well, despite the attempt to get knocked down. Looks like the beginning of a run.
This is brand spankin news!!
I like it if we stay above 7
SUNRISE, FL / ACCESSWIRE / April 15, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today that it will hold a 1st Quarter Review Conference Call on Thursday, April 23rd, 2015 at 4:30 PM EDT. The call will highlight research and development, business and corporate accomplishments for the first quarter of 2015 and goals for the second quarter. Webinar and dial-in numbers for the conference call will be posted on Monday, April 20, 2015.
"We continue to advance on our plan and pathway to profitability," said Mike Tomas, President and Chief Executive Officer. "Each of our operating divisions: Bioheart, US Stem Cell Training, Vetbiologics and US Stem Cell Clinic have made strategic and tactical gains in the first quarter and we expect to build on our positive momentum as we continue through this year. We look forward to updating you on our accomplishments on April 23rd."
About Bioheart, Inc.
Bioheart, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.
Our business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.
US Stem Cell Training, ("SCT"), an operating division of Bioheart, Inc., is a content developer of regenerative medicine / cell therapy informational and training materials for physicians and patients. SCT also provides in-person and online training courses which are delivered through in-person presentations at SCT's state of the art facilities and globally at university, hospital and physician's office locations as well as through online webinars. Additionally, SCT provides hands-on clinical application training for physicians and health care professionals interested in providing regenerative medicine / cell therapy procedures.
Vetbiologics, ("VBI"), an operating division of Bioheart, Inc., is a veterinary regenerative medicine company committed to providing veterinarians with the ability to deliver the highest quality regenerative medicine therapies to dogs, cats and horses. VBI provides veterinarians with extensive regenerative medicine capabilities including the ability to isolate regenerative stem cells from a patient's own adipose (fat) tissue directly on-site within their own clinic or stall-side. VBI regenerative medicine technologies are designed, implemented and produced according to the highest standards. VBI follows the FDA guidelines for human cellular therapy production which means each product produced must be validated and must pass stringent criteria.
US Stem Cell Clinic, LLC, ("SCC"), a partially owned investment of Bioheart, Inc., is a physician run regenerative medicine / cell therapy clinic providing cellular treatments for patients afflicted with neurological, autoimmune, orthopedic and degenerative diseases. SCC is operating in compliance with the FDA 1271s which allow for same day medical procedures to be considered the practice of medicine. We isolate stem cells from bone marrow and adipose tissue and also utilize platelet rich plasma.
Media Contact:
Carissa Matton
Bioheart, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Florida 33325
Phone: 772.285.8511
cmatton@bioheartinc.com
SOURCE: Bioheart, Inc.
I got this email today.
Dear Colleagues,
I have been getting many inquiries regarding the current regulatory status of stromal vascular fraction (SVF) used in clinic. In fact, I have even heard rumors that we were shut down by the FDA and prevented from doing SVF. This is simply untrue and there have been no changes in the regulatory status of medical procedures done in clinic including SVF.
The FDA has recently released a draft guidance document regarding the use of human cell and tissue products used during the same surgical procedure from adipose tissue and has requested comments from the public on this guidance. Please note that guidance documents represent the FDA's "current thinking on the scope" of the topic. "FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the FDA's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA's guidances means that something is suggested or recommended, but not required."
We do not believe that the current draft guidance document will affect our ability to offer in-clinic cell therapy from fat to our patients. The FDA's document has elicited much resistance from the public. Additionally, highly respected organizations such as AABB Center for Cellular Therapies and The Academy of Regenerative Medicine have voiced their opposition. Even if the document were published as is, we do not believe it gives the FDA legal authority to stop these procedures.
It is impossible to predict what the FDA will do regarding any in clinic therapies so I can only tell you what has happened in the past. In December of 2014, the FDA visited our lab as well as three physicians who are doing SVF procedures. The FDA took no action against anyone and did not stop the SVF procedures. Many of you have seen that these procedures can provide benefit to patients who have failed other therapies. Our primary goal has been and will continue to be safety and well-being for our patients.
Feel free to contact me if you have any questions or would like to discuss this further.
Regards,
Kristin Comella
Chief Scientific Officer
BIOHEART INC.
Isn't*
I feel you GS. BHRT is going away. The company's position is strong. You and I both know this as longs.
This is a complete joke. It defines "joke"
Same here.
We are at a very interesting crossroad... Best position we have ever been in and yet, price per share does not reflect our position.
It's expected early May.
Lol, quote, "lol"
Sunrise, FL – March 17, 2015 – Bioheart, Inc., a Florida Corporation (BHRT.OB), an emerging enterprise in the regenerative medicine / cellular therapy industry is pleased to announce, following the release of its Form 10-K Annual Report, key 2014 accomplishments including but not limited to:
1.A 2,040% increase in year over year revenues to $2.1 million in 2014 from $0.1 million in 2013,
2.A 28% decrease in year over year net loss to ($2.25) million in 2014 from ($3.14) million in 2013,
3.A 42% decrease in year over year cash used in operating activities to $1.1 million in 2014 from $1.9 million in 2013,
4.A 20% reduction ($2.3 million) in year over year current liabilities to $11.1 million at December 31, 2014 from $13.4 million at December 31, 2013, and
5.A 20% reduction in the Company’s working capital deficit.
“Bioheart is moving in the right direction,” said Mike Tomas, President and Chief Executive Officer. “We are extremely proud of what we have accomplished in 2014 and through an extraordinary effort have set the stage for continuing improvements in both income statement and balance sheet performance in 2015. In 2015, we will continue our efforts to reshape Bioheart into a growth oriented, profit generating company capable of delivering regenerative / cellular therapies and products globally while advancing our clinical development pipeline to market. In the coming months, we look forward to announcing new strategic relationships that will introduce new opportunities for growth as well as jump starting long delayed clinical programs. I extend my sincere thanks to Dr. William P. Murphy, Jr., our Chairman, our Board of Director, Kristin Comella, our Chief Scientific Officer, the Bioheart Team and most especially you, our shareholders for your continuing support, commitment and dedication to our Company. We are excited about Bioheart’s future and we look forward to keeping you posted on our progress.”
It's a dead link
Imo this is going to be the year BioHearts value is recognized by the market.
Sure thing, no problem
Santa Monica CA March 31st 2015- BioLeonhardt a Leonhardt Ventures Co. founded in 2008 announced today a special deal to shareholders of Bioheart Inc. BioLeonhardt is developing an implantable programmable re-fillable stem cell pump and microcurrent regeneration stimulator device for organ regeneration including damaged and weakened hearts. The device has a pacemaker like lead with a central infusion lumen that delivers cells growth factors nutrients and microcurrent regeneration signals to the heart. This technology is meant to compliment the muscle stem cell and adipose tissue derived cell compositions developed by Bioheart Inc. since 1999. The BioLeonhardt device may serve as a 2nd generation repeat dose delivery system for the Bioheart Inc. cell compositions - www.bioleonhardt.com
http://www.menafn.com/1094146460/BioLeonhardt-Offers-Special-Deal-to-Bioheart-Inc-Shareholders
Sunrise, FL – March 17, 2015 – Bioheart, Inc., a Florida Corporation (BHRT.OB), an emerging enterprise in the regenerative medicine / cellular therapy industry is pleased to announce, following the release of its Form 10-K Annual Report, key 2014 accomplishments including but not limited to:
1.A 2,040% increase in year over year revenues to $2.1 million in 2014 from $0.1 million in 2013,
2.A 28% decrease in year over year net loss to ($2.25) million in 2014 from ($3.14) million in 2013,
3.A 42% decrease in year over year cash used in operating activities to $1.1 million in 2014 from $1.9 million in 2013,
4.A 20% reduction ($2.3 million) in year over year current liabilities to $11.1 million at December 31, 2014 from $13.4 million at December 31, 2013, and
5.A 20% reduction in the Company’s working capital deficit.
“Bioheart is moving in the right direction,” said Mike Tomas, President and Chief Executive Officer. “We are extremely proud of what we have accomplished in 2014 and through an extraordinary effort have set the stage for continuing improvements in both income statement and balance sheet performance in 2015. In 2015, we will continue our efforts to reshape Bioheart into a growth oriented, profit generating company capable of delivering regenerative / cellular therapies and products globally while advancing our clinical development pipeline to market. In the coming months, we look forward to announcing new strategic relationships that will introduce new opportunities for growth as well as jump starting long delayed clinical programs. I extend my sincere thanks to Dr. William P. Murphy, Jr., our Chairman, our Board of Director, Kristin Comella, our Chief Scientific Officer, the Bioheart Team and most especially you, our shareholders for your continuing support, commitment and dedication to our Company. We are excited about Bioheart’s future and we look forward to keeping you posted on our progress.”
I agree, surprise Gems indeed.